SAB BIOTHERAPEUTICS INC (SABS) Stock Analyst Ratings
USA - NASDAQ:SABS - US78397T2024 - Common Stock
3.02 USD
-0.01 (-0.33%)
2.99 USD
-0.03 (-0.99%)
ChartMill assigns a Buy % Consensus number of 85% to SABS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.01. This target is 198.34% above the current price.
SABS was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about SABS.
In the previous month the buy percentage consensus was at a similar level.
SABS was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-17 | Leerink Partners | Initiate | Outperform |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-09 | Craig-Hallum | Initiate | Buy |
| 2024-09-12 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-09-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-28 | Oppenheimer | Initiate | Outperform |
| 2024-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-07 | Brookline Capital | Initiate | Buy |
| 2024-05-21 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-01-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-05 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2023-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-15 | Chardan Capital | Reiterate | Buy -> Buy |
SAB BIOTHERAPEUTICS INC / SABS FAQ
What do analysts expect the price target to be for SAB BIOTHERAPEUTICS INC (SABS)?
12 analysts have analysed SABS and the average price target is 9.01 USD. This implies a price increase of 198.34% is expected in the next year compared to the current price of 3.02.
How do analysts rate SAB BIOTHERAPEUTICS INC (SABS)?
The consensus rating for SAB BIOTHERAPEUTICS INC (SABS) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.